← All trials
NCT05967117
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 24, 2023
- Primary completion
- Oct 31, 2024
- Completion date
- Nov 30, 2024
- First posted
- Aug 1, 2023
- Last posted
- Dec 28, 2023
- Enrollment
- 308
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Catholic University of KoreaLead sponsor
- Taejoon Pharm Co., Ltd.Collaborator
- Catholic University of KoreaSponsor investigator
- Catholic University of KoreaStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.